NCT00401544 2014-01-29
Darbepoetin Alfa With or Without Intravenous (IV) Iron
Amgen
Phase 2 Completed
Clinical Trials
8 trialsNCT00989092 2014-01-29
Darbepoetin Alfa and Anemia of Cancer
Amgen
Phase 2 Terminated
NCT00386152 2013-07-19
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT00144131 2013-05-24
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
Amgen
Phase 2 Completed
NCT00111462 2013-05-08
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
Amgen
Phase 2 Completed
NCT00239239 2010-03-05
Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
Amgen
Phase 2 Completed
NCT00120705 2009-03-25
Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy
Amgen
Phase 2 Completed
NCT00210002 2006-11-14
Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced
Institut Claudius Regaud
Phase 2 Terminated